
price close busi juli
domin global leader next
gener sequenc instrument
biomed devic servic
materi lower fy guid pt
share after-hour compani announc prelim
revenue miss cut revenue growth guid size miss
guid remind us pre-announc x-ten day year ago
differ high-throughput novaseq consum crank
y/i miss mostli due push-out larg govern pop seq project
disappoint re-rat growth chang funnel
demand sequenc reveal anyth chang competit
dynam reiter buy rate lower pt
major revenu miss close pre-announc revenu
flat y/i ilmn
guid due expect revenu shortfal popul genom
initi shortfal array revenu due on-going weak dtc
genom test shortfal non-high-throughput sequenc system
consum spoke indic popul
genom shortfal mostli due instrument shortfal permit
say govern program fulfil larg order believ
us uk franc singapor anoth countri plan
fulfil order later year manag indic fund issu
matter get signoff variou constitu within govern
longer complic process expect go forward manag remain
optimist deep funnel pop seq initi contempl longer
period close order previous expect partial explain impli
guid obvious huge re-rat downward
lower guid lower revenue growth project
impli guide-down due lower expect dtc
genet test longer ramp-up period pop seq project lower expect
sale non-high-throughput sequenc system consum part due
pharma partner program surmis bm push
expect sequenc revenue growth vs ilmn prior mid-
teen guid includ sequenc consum growth vs
ilmn prior guid sequenc servic slightli y/i
vs expect array revenu declin vs prior flat
y/i guid expect lower ep guid call juli
dtc continu disappoint base convers logic
intuit ancestri order light expect
set realli disappoint dtc test unfortun
seem visibl bring easier comp
appear confid dtc test bounc back point unclear
us happen perhap state
lower array revenu guid declin y/i predominantli due
lower dtc test note neg read-through hold-rat orasur
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
silver line indic novaseq consum volum grew
y/i q/q driven strong interest flow cell strip
multi-system pop seq deal miss june cutoff novaseq system
shipment came ahead expect note nextseq system
consum grew sequenti y/i average pull-through per nextseq system
within target rang annual continu expect
novaseq pull-through per system higher expect
novaseq system shipment flat slightli compar model
placement vs
call offer expand guidanc explan plan provid full
updat guidanc earn confer call et juli
plan updat model follow call reduc price target
base lower multipl vs previou unchang ep
estim
time popul genom project control prior yesterday
updat investor concern compani guid revenue
ramp vs pop genom initi turn concern
appropri recent meet manag indic good
line sight global program track would account
ramp peg sampl us
four project base yesterday updat forecast lower
expect learn detail call
dtc mysteri meet manag recent specul
futur dtc custom could launch tier offer could
includ sequenc array specul year
believ want counter critic lack clinic util
health result need move sequenc health offer think
need address privaci concern think whether want
offer genet counsel line think correct may requir
addit develop regulatori time thu view growth rate us
dtc test risk continu believ us dtc recoveri may
occur instead may creat headwind orasur
labcorp lh nyse hold view said think temporari
slowdown array could partial forgiven beat high-margin sequenc
new updat continu expect close acquisit pacbio
summer chang phase dialogu uk phase
ftc us indic deal closur progress plan peg
chanc deal approv summer note deal spread widen
sinc call
buy unchang target price juli
biomed devic servic
detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact inform appear front page report
buy unchang target price juli
biomed devic servic
buy unchang target price juli
biomed devic servic
buy unchang target price juli
biomed devic servic
buy unchang target price juli
biomed devic servic
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti llc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin juli et
date time product juli et
pt use multipl adj ep estim
laboratori corpor america hold lh
pt use multipl adj ep estim
pt use multipl revenu estim million discount back year plu net
risk achiev target price valuat
believ key risk includ major new product launch novaseq instrument premium valuat excess
peer group risk associ demand pace novaseq placement hiseq unit decommiss
competit noise/tract though believ meaning competit risk well bay nih/govern budgets/
spend particularli foreign govern like japan genom research center regulatori risk fda addit
risk factor less concern includ typic medic technolog risk price instrument consum risk
associ move test clinic increas compani focu bioinformat long-term also
highlight spend scale helix
laboratori corpor america hold lh
labcorp integr covanc macroeconom weak may threaten volum margin unemploy rate
hover around variou macroeconom headwind potenti reduc demand diagnost servic especi drugs-
of-abus doa pre-employ test rel cyclic busi segment roughli volum revenu
healthcar reform may lead medicar reimburs cut labcorp deriv revenu medicar medicaid
program lab industri provid face risk declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost believ all-in medicar reimburs rate lab increas
modestli expect medicar reimburs declin approxim labcorp face competit threat
could slow growth labcorp compet industri leader quest diagnost along numer smaller independ nich
clinic laboratori quest slightli larger scale scope labcorp smaller competitor may prove nimbl
innov labcorp australian-bas sonic healthcar build signific presenc
compet labcorp acquisit northeast lh compet bio-refer lab compani deriv
revenu higher-margin esoter test negoti health plan plan includ manag care organ
health insur provid repres approxim compani volum revenu compani largest health
plan exclus contract end repres approxim revenu estim
labcorp compet aggress quest contract health plan larg price margin contract length
regulatori risk exist new test indic delay denial approv would neg affect compani commerci risk
exist product reimburs competit continu weak economi could inhibit growth orasur drug
abus test busi risk associ intern sale infecti diseas product risk relat fund hiv
buy unchang target price juli
biomed devic servic
particularli unit state competit risk gener hiv product dna genotek subsidiari larg
custom failur continu work would advers impact busi
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
